Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients With Metastatic Nonsquamous NSCLC
In this study of patients with metastatic nonsquamous NSCLC who received maintenance pemetrexed and pembrolizumab, patients who stopped pemetrexed due to toxicity experienced similar outcomes to those who continued with pemetrexed. The optimal duration of maintenance chemotherapy should be further evaluated in the immunotherapy era.
Authors
- Wade T. Iams (ORCID: https://orcid.org/0000-0003-2109-298X)
- Spencer Lessans
- Heidi Chen
- M Lu (ORCID: https://orcid.org/0000-0002-7965-209X)
- Michael Libre (ORCID: https://orcid.org/0000-0003-0825-194X)
- Shreya Bhatia (ORCID: https://orcid.org/0000-0002-3661-7438)
Institutions
- Vanderbilt University (US)
- Vanderbilt-Ingram Cancer Center
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-08-25
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100717
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42